Pharmafile Logo
Pharmafocus logo
Advanced Search

J&J

Showing 15 posts of 227 posts found.

J&J image

J&J pleads guilty over children’s contaminated medicine

March 12, 2015
Manufacturing and Production, Sales and Marketing FDA, J&J, JJ, McNeil, OTC, Tylenol, consta, hamburg, recall

Johnson & Johnson’s consumer division McNeil has pleaded guilty and will pay fines of $25 million for wrongdoings regarding its …

News

NICE recommends hep C and bowel treatments

February 26, 2015
Sales and Marketing AbbVie, Humira, J&J, JJ, Janssen, Merck, Remicade, Simponi, olysio

Three drugs to treat chronic bowel condition ulcerative colitis and one for hepatitis C will be funded by the NHS …

News
J&J image

J&J leukaemia drug gets FDA go-ahead

January 30, 2015
Sales and Marketing FDA, J&J, JJ, Janssen, The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s macroglobulinemia (WM) – a rare indol, Waldenström’s Macroglobulinemia, ibrutinab, imbruvica, johnson

The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s …

News
Ebola vaccine image

Scientists warn Ebola virus is mutating

January 29, 2015
Research and Development, Sales and Marketing Africa, Ebola, GAVI, GSK, Institut Pasteur, J&J, JJ, guinea

Researchers in France studying the Ebola epidemic say the virus has mutated making it potentially even more contagious. Scientists based …

News
Xarelto image

NICE recommends Bayer heart attack drug

January 26, 2015
Sales and Marketing ACS, Bayer, J&J, JJ, NICE, Xarelto, q4, rivaroxaban

NICE has recommended Xarelto in final draft guidance as an option for preventing blood clots in people who have had …

News
J&J image

Olysio and Xarelto boost J&J’s Q4

January 21, 2015
Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four

Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …

News
Janssen image

Isis and J&J sign RNA deal

January 8, 2015
Research and Development, Sales and Marketing Isis, J&J, JJ, Janssen, RNA, gastrointestinal tract

Isis Pharmaceuticals is collaborating with Johnson & Johnson’s pharma unit Janssen to develop antisense drugs to treat autoimmune disorders. The …

News
Janssen image

Vectura and J&J shake on asthma/COPD deal

January 6, 2015
Research and Development, Sales and Marketing COPD, J&J, JJ, Janssen, asthma, johnson, rezolsta, tybost, vectura

British firm Vectura has entered an agreement with Johnson & Johnson’s pharma unit Janssen to develop therapies for asthma and …

News
Vaccine image

Gavi pledges $300 million for Ebola vaccines

December 12, 2014
Manufacturing and Production, Sales and Marketing GAVI, GSK, GlaxoSmithKline, J&J, JJ, Merck, Vaccine, WHO, newlink

The global vaccines alliance Gavi has committed to buying Ebola vaccines as soon as the World Health Organization recommends one …

News
Ranbaxy image

Ranbaxy launches J&J biosimilar in India

December 5, 2014
Manufacturing and Production, Sales and Marketing CHMP, FDA, India, J&J, JJ, Ranbaxy, Remicade, nlem, nppa

Ranbaxy has launched the first biosimilar of Johnson & Johnson’s Remicade (infliximab) in India, marking the firm’s entry into monoclonal …

News
J&J image

J&J announces ‘major commitment’ to Ebola effort

October 22, 2014
Sales and Marketing Crucell, Ebola, J&J, JJ, Vaccine, bavarian, johnson, niaid

Johnson & Johnson will invest $200 million to accelerate and significantly expand the production of its Ebola vaccine programme. The …

News
J&J image

J&J bets $1.75 billion on virology

October 1, 2014
Research and Development, Sales and Marketing AL-8176, Alios BioPharma, J&J, JJ, Janssen, sovaldi, viral

Johnson & Johnson has signed a deal to acquire Alios BioPharma, a privately-held company focussed on developing therapies for viral …

News

Senior J&J head appointed by Synageva

September 23, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, rob bazemore, synageva

US biopharma firm Synageva has appointed Robert Bazemore as its chief operating officer. Reporting directly to the president and chief …

Appointment
jj_building_0

New drugs see J&J sales rise

July 17, 2014
Medical Communications, Sales and Marketing J&J, JJ, Q2, hepatitis C, olysio, sovaldi

Johnson & Johnson saw sales rise 9.1% to $19.5 billion year on year on the back of a strong performance …

News
J&J image

J&J completes $4 billion OCD sale

July 2, 2014
Sales and Marketing J&J, JJ, Johnson and Johnson, Ortho-Clinical Diagnostics, carlyle, ocd

Johnson & Johnson has sold its Ortho-Clinical Diagnostics (OCD) business to private equity investor The Carlyle Group for ‘approximately $4 …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026